Literature DB >> 21541834

[Autoinflammatory syndromes/fever syndromes].

J Schedel1, B Bach, J B Kümmerle-Deschner, I Kötter.   

Abstract

Hereditary periodic (fever) syndromes, also called autoinflammatory syndromes, are characterized by relapsing fever and additional manifestations such as skin rashes, mucosal manifestations, or joint symptoms. Some of these disorders present with organ involvement and serological signs of inflammation without fever. There is a strong serological inflammatory response with an elevation of serum amyloid A (SAA), resulting in an increased risk of secondary amyloidosis. There are monogenic disorders (familial mediterranean fever (FMF), hyper-IgD-syndrome (HIDS), cryopyrin-associated periodic syndromes (CAPS), "pyogenic arthritis, acne, pyoderma gangrenosum" (PAPA), and "pediatric granulomatous arthritis (PGA) where mutations in genes have been described, which in part by influencing the function of the inflammasome, in part by other means, lead to the induction of the production of IL-1β. In "early-onset of enterocolitis (IBD)", a functional IL-10 receptor is lacking. Therapeutically, above all, the IL-1 receptor antagonist anakinra is used. In case of TRAPS and PGA, TNF-antagonists (etanercept) may also be used; in FMF colchicine is first choice. As additional possible autoinflammatory syndromes, PFAPA syndrome (periodic fever with aphthous stomatitis, pharyngitis and adenitis), Schnitzler syndrome, Still's disease of adult and pediatric onset, Behçet disease, gout, chronic recurrent multifocal osteomyelitis (CRMO) and Crohn's disease also are mentioned.

Entities:  

Mesh:

Year:  2011        PMID: 21541834     DOI: 10.1007/s00105-010-2124-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  86 in total

1.  Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome.

Authors:  E Drewe; M L Huggins; A G Morgan; M J D Cassidy; R J Powell
Journal:  Rheumatology (Oxford)       Date:  2004-08-17       Impact factor: 7.580

2.  Schnitzler syndrome: a case report of successful treatment using the anti-CD20 monoclonal antibody rituximab.

Authors:  K M Ramadan; H A Eswedi; M R El-Agnaf
Journal:  Br J Dermatol       Date:  2007-03-13       Impact factor: 9.302

3.  Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient.

Authors:  I Mitroulis; V P Papadopoulos; T Konstantinidis; K Ritis
Journal:  Neth J Med       Date:  2008-12       Impact factor: 1.422

4.  Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

Authors:  Melike Melikoglu; Izzet Fresko; Cem Mat; Yilmaz Ozyazgan; Feride Gogus; Sebahattin Yurdakul; Vedat Hamuryudan; Hasan Yazici
Journal:  J Rheumatol       Date:  2005-01       Impact factor: 4.666

5.  Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis.

Authors:  Carlos D Rosé; Trudy M Doyle; Gail McIlvain-Simpson; Jessica E Coffman; James T Rosenbaum; Michael P Davey; Tammy M Martin
Journal:  J Rheumatol       Date:  2005-02       Impact factor: 4.666

6.  Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Authors:  Hal M Hoffman; Martin L Throne; N J Amar; Mohamed Sebai; Alan J Kivitz; Arthur Kavanaugh; Steven P Weinstein; Pavel Belomestnov; George D Yancopoulos; Neil Stahl; Scott J Mellis
Journal:  Arthritis Rheum       Date:  2008-08

Review 7.  The use of interferon alpha in Behçet disease: review of the literature.

Authors:  Ina Kötter; Ilhan Günaydin; Manfred Zierhut; Nicole Stübiger
Journal:  Semin Arthritis Rheum       Date:  2004-04       Impact factor: 5.532

8.  Use of canakinumab in the cryopyrin-associated periodic syndrome.

Authors:  Helen J Lachmann; Isabelle Kone-Paut; Jasmin B Kuemmerle-Deschner; Kieron S Leslie; Eric Hachulla; Pierre Quartier; Xavier Gitton; Albert Widmer; Neha Patel; Philip N Hawkins
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

9.  Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome.

Authors:  Nobuo Kanazawa; Ikuo Okafuji; Naotomo Kambe; Ryuta Nishikomori; Mami Nakata-Hizume; Sonoko Nagai; Akihiko Fuji; Takenosuke Yuasa; Akira Manki; Yoshihiko Sakurai; Mitsuru Nakajima; Hiroko Kobayashi; Ikuma Fujiwara; Hiroyuki Tsutsumi; Atsushi Utani; Chikako Nishigori; Toshio Heike; Tatsutoshi Nakahata; Yoshiki Miyachi
Journal:  Blood       Date:  2004-09-30       Impact factor: 22.113

10.  Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome.

Authors:  Kazuki Takada; Ivona Aksentijevich; Vijayabhanu Mahadevan; Jane A Dean; Richard I Kelley; Daniel L Kastner
Journal:  Arthritis Rheum       Date:  2003-09
View more
  2 in total

Review 1.  [Leg discoloration].

Authors:  L Unger; U Wollina; J Machetanz; C Stelzner; S Schellong
Journal:  Internist (Berl)       Date:  2013-11       Impact factor: 0.743

Review 2.  [Skin disorders in malignant hematologic diseases].

Authors:  M Schmid-Wendtner; T Hornung; M Meurer; C-M Wendtner
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.